NCT02437253 2017-09-15
Effects of Adalimumab in Mucopolysaccharidosis Types I, II and VI
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Phase 1/2 Completed
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Office of Rare Diseases (ORD)